Table 1.

Baseline characteristics of the study cohort. Age [years], cyclophosphamide dosage [mg], PaO₂/FiO₂ ratio [mmHg/%], ventilation period, delay from ILD diagnosis to first cyclophosphamide administration, survival since cyclophosphamide administration and follow-up period [days] are presented as mean with standard deviation (SD) and median with interquartile range (Q1-Q3). Sex, diagnoses, pathologic laboratory values, supportive therapy, ventilation mode, veno-venous extra corporal membrane oxygenation (ECMO), laboratory values and survival status are presented with the absolute and relative (in %) proportions